Fosun Pharma to import 100 mln doses of BioNTech's COVID-19 vaccine to China

A woman holds a medical syringe and a small bottle labeled "Coronavirus COVID-19 Vaccine
A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic

Dec 16 (Reuters) - Shanghai Fosun Pharmaceutical Group (600196.SS) said on Wednesday that BioNTech SE (22UAy.DE) will supply at least 100 million doses of its COVID-19 vaccine, if approved, to mainland China next year.

China has not announced supply deals with Western drugmakers, which instead have partnered with private companies in the country. read more

Fosun Pharma will make an initial payment of 125 million euros ($151.84 million) by the end of the year for 50 million doses.

Pfizer and BioNTech's COVID-19 vaccine has already received approval for emergency use in several countries, including the U.S., UK, and Singapore.

Fosun Pharma has brought two candidates of BioNTech's vaccine into clinical trials in China. Neither has yet received approval from the medical regulator.

The companies have initiated a Phase 2 clinical trial of 960 participants for its vaccine candidate BNT162b2 in Jiangsu Province, China.

($1 = 0.8232 euros)

Reporting by Nikhil Kurian Nainan in Bengaluru Editing by Shri Navaratnam

Our Standards: The Thomson Reuters Trust Principles.